Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 1999

View Archived Issues

FDA approves new H. pylori diagnostic test

NeoRx updates cancer clinical trial progress

FDA Advisory Committee to review Evacet on September 16

QLT begins phase II trial for psoriasis treatment

Anika completes patient enrollment in Orthovisc phase III trial

Dynavax completes patient enrollment and dosing in phase I ragweed allergy trial

New protease inhibitor to be tested in multicenter trial

Millennium delivers eighth antibacterial drug target to Wyeth-Ayerst

NeuroSearch pipeline continues to progress in H1 1999

Novel VLA-4 antagonists prepared and evaluated at Novartis

Korean researchers identify antiinflammatory/analgesic agent from native shrub extract

Bayer research yields new anti-CMV compounds

Novel compounds from Rhone-Poulenc Rorer act as factor Xa inhibitors

Selective endothelin ETB receptor antagonists disclosed by Shionogi

Two new RAR antagonists emerge from retinoid research program at Bristol-Myers Squibb

ACS highlights: DuPont investigates dual MMP/TNF-alpha production inhibitors

Phase I study of Avant's vaccine delivery system shows promising results

Steroidal "ante drugs" from Affymax have potent activity in the lungs, short half-life in plasma

ACS research news: Neurocrine Biosciences presents newest CRF antagonist

Bio-Technology General granted additional patent allowance for oxandrolone

Tezosentan, a novel ETA/ETB antagonist for parenteral treatment of acute hemodynamic conditions

Lilly presents orally active growth hormone secretagogues at ACS meeting

Cystic Fibrosis Foundation awards research grant to PathoGenesis

Merck KGaA's novel vitronectin antagonist EMD-121974 enters clinical testing in various cancers

Procept announces NCI-sponsored trials of its chemosensitizing agent

Adenosine A1 receptor agonist NNC-21-0147 is a potent neuroprotectant without CV effects

Cangene initiates phase III trial of Leucotropin in new indication